Manchester Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Manchester Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,057	Closed	-$143K	–	969
2014 Q4	$143K	Hold	5,057	–	–	0.02%	446
2014 Q3	$128K	Hold	5,057	–	–	0.02%	500
2014 Q2	$148K	Hold	5,057	–	–	0.02%	454
2014 Q1	$131K	Buy	+5,057	New	+$135K	0.02%	461

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Manchester Capital Management's PTLA Position: Q1 2015 in Review

Manchester Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2015, closing a stake of 5,057 shares — an estimated $143K sold.

Manchester Capital Management first reported a position in PTLA in Q1 2014 and held it in 4 quarters. The position peaked at $148K in Q2 2014. 160 funds tracked by Wall St. Rank hold PTLA as of Q1 2015.

Manchester Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
Manchester Capital Management sold 5,057 Portola Pharmaceuticals, Inc. shares in Q1 2015, an estimated $143K.
Manchester Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
Manchester Capital Management's Portola Pharmaceuticals, Inc. position peaked at $148K in Q2 2014.
160 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2015.

Based on Manchester Capital Management's 13F filing for Q1 2015, filed 7 May 2015.